Jazz to Acquire Actio Biosciences for Rare Epilepsy Drug
Dublin, Ireland & San Diego, California, USA, August 10, 2026 Jazz Pharmaceuticals plc and Actio Biosciences, Inc. have announced...
AI drug discovery artificial intelligence Autoimmune Disease biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology Ophthalmology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine solid tumors targeted therapy
Dublin, Ireland & San Diego, California, USA, August 10, 2026 Jazz Pharmaceuticals plc and Actio Biosciences, Inc. have announced...
RESEARCH TRIANGLE PARK, N.C., Aug. 3, 2026 Opus Genetics, Inc. has completed patient enrollment in its registrational Phase 3...
